The ditans, a new class for acute migraine: Minireview

@article{Rissardo2020TheDA,
  title={The ditans, a new class for acute migraine: Minireview},
  author={J. Rissardo and Ana Let{\'i}cia Fornari Caprara},
  journal={Journal of Current Research in Scientific Medicine},
  year={2020},
  volume={6},
  pages={11 - 14}
}
Lasmiditan (LDT), a new drug, was approved by the Food and Drug Administration in October 2019 for acute migraines with or without aura. LDT belongs to a new class of drugs “-ditans,” in which the mechanism is different from the triptans since it does not show vasoactive effects. The “-ditans” are more likely to be involved with the trigeminal system without causing vasoconstriction because of its low affinity for 5-HT1B receptors and highly selective 5-HT1F receptor agonist. The LDT probably…